• Saturday,September 28,2024
gecos.fr
X

Current scenario on non-nucleoside reverse transcriptase inhibitors (2018-present) - ScienceDirect

$ 16.50

5 (784) In stock

Share

Chemical diversity and activity profiles of HIV-1 reverse

Cardiovascular disease and risk assessment in people living with

Reverse-Transcriptase Inhibitor - an overview

Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief

Development of non-nucleoside reverse transcriptase inhibitors

The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside

The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside

Nutrients, Free Full-Text

Chemical structures of nonnucleoside reverse transcriptase

Approved HIV reverse transcriptase inhibitors in the past decade